These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36709172)

  • 1. [Clinical features and prognosis of 166 cases of MYC/BCL2 double-expression diffuse large B-cell lymphoma].
    Tang SH; Tian L; Zhao W; Wang J; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2022 Sep; 43(9):771-777. PubMed ID: 36709172
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of lymphocyte-to-monocyte ratio and histone methyltransferase G9a histone methyltransferase in patients with double expression lymphoma: A retrospective observational study.
    Xu P; Sun X; Song X; Peng Y; He B; Wu Z; Zhu J
    Medicine (Baltimore); 2021 Jan; 100(4):e24449. PubMed ID: 33530253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60¬†years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
    Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome.
    Dodero A; Guidetti A; Marino F; Tucci A; Barretta F; Re A; Balzarotti M; Carniti C; Monfrini C; Chiappella A; Cabras A; Facchetti F; Pennisi M; Rahal D; Monti V; Devizzi L; Miceli R; Cocito F; Farina L; Ricci F; Rossi G; Carlo-Stella C; Corradini P
    Haematologica; 2022 May; 107(5):1153-1162. PubMed ID: 34289655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myc rearrangement and concurrent high protein expression of C-Myc/Bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma.
    Wang X; He J; He H; Shuai Y; Wang L; Li Y; Huang Y; Yu K; Zhao M; Xie T; Li D
    Ann Diagn Pathol; 2023 Oct; 66():152165. PubMed ID: 37348414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].
    Yang X; Chen S; Qi Y; Xu XY; Guan X; Yang YC; Liu YX; Guo YH; Gong WC; Gao YN; Wang XH; Li W; Li LF; Fu K; Zhang HL; Meng B
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jun; 42(6):487-494. PubMed ID: 34384155
    [No Abstract]   [Full Text] [Related]  

  • 8. MYC expression in concert with BCL2 and BCL6 expression predicts outcome in Chinese patients with diffuse large B-cell lymphoma, not otherwise specified.
    Yan LX; Liu YH; Luo DL; Zhang F; Cheng Y; Luo XL; Xu J; Cheng J; Zhuang HG
    PLoS One; 2014; 9(8):e104068. PubMed ID: 25090026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical characteristics and prognosis of primary and secondary diffuse large B-cell lymphoma of the pancreas].
    Huo YJ; Zhang MC; Shi Q; Qin W; Shi ZY; Wang L; Cheng S; Xu PP; Zhao WL
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):55-61. PubMed ID: 36987724
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical Significance of
    Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
    Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
    [No Abstract]   [Full Text] [Related]  

  • 11. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
    Miyamoto K; Kobayashi Y; Maeshima AM; Taniguchi H; Nomoto J; Kitahara H; Fukuhara S; Munakata W; Maruyama D; Tobinai K
    Int J Hematol; 2016 Jun; 103(6):693-702. PubMed ID: 27095041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma.
    Chen H; Qin Y; Liu P; Yang J; Gui L; He X; Zhang C; Zhou S; Zhou L; Yang S; Shi Y
    Mol Diagn Ther; 2023 Jan; 27(1):75-86. PubMed ID: 36401148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic evaluation of P53 and BCL2 proteins in MYC/BCL2 double expression DLBCL].
    Huang P; Chen S; Yang X; Lei YY; Xu XY; Liu YX; Guo YH; Pan Y; Wang XH; Zhang HL; Fu K; Meng B
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):589-593. PubMed ID: 32397023
    [No Abstract]   [Full Text] [Related]  

  • 16. [Analysis of survival and prognosis in 409 newly diagnosed patients with diffuse large B-cell lymphoma].
    Wen J; Zhou J; Liu Z; Liu T; Xu C
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):318-24. PubMed ID: 24759020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upfront autologous hematopoietic stem cell transplantation for high-risk patients with double-expressor diffuse large B cell lymphoma.
    Kim YR; Yoon SO; Kim SJ; Cheong JW; Chung H; Lee JY; Jang JE; Kim Y; Yang WI; Min YH; Kim JS
    Ann Hematol; 2020 Sep; 99(9):2149-2157. PubMed ID: 32390113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 19. Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy.
    Takahashi H; Miura K; Nakagawa M; Sugitani M; Amano Y; Kurita D; Sakagami M; Ohtake S; Uchino Y; Kodaira H; Iriyama N; Kobayashi S; Hojo A; Kobayashi Y; Hirabayashi Y; Kusuda M; Hatta Y; Nakayama T; Takei M
    Leuk Lymphoma; 2016 Dec; 57(12):2784-2790. PubMed ID: 27071312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
    Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
    Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.